Nasdaq Crtx News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq crtx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Crtx Today - Breaking & Trending Today
Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s stock price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.14 and traded as high as $1.39. Cortexyme shares last traded at $1.34, with a volume of 51,197 shares traded. Cortexyme Stock Performance […] ....
Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.18 and traded as high as $1.20. Cortexyme shares last traded at $1.15, with a volume of 36,188 shares. Cortexyme Price Performance The company has a market […] ....
Cortexyme, Inc. (NASDAQ:CRTX – Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.18 and traded as high as $1.51. Cortexyme shares last traded at $1.50, with a volume of 64,636 shares. Cortexyme Price Performance The stock has a 50-day moving average […] ....
Cortexyme, Inc. (NASDAQ:CRTX – Get Rating)’s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.00 and traded as high as $1.68. Cortexyme shares last traded at $1.67, with a volume of 44,897 shares trading hands. Cortexyme Price Performance The stock has a […] ....
Cortexyme (NASDAQ:CRTX – Get Rating) and Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations. Volatility & Risk Cortexyme has a beta of 1.4, […] ....